ARQ 069 is used as a selective inhibitor of FGFR1 and FGFR2 kinases, targeting their non-phosphorylated, inactive forms in a non-ATP-competitive manner; it inhibits FGFR1/FGFR2 autophosphorylation with IC50 values of 2.8 μM and 1.9 μM, respectively, and exhibits enantioselective inhibition of FGFR activity.